Racial differences in characteristics and prognoses between Asian and white patients with nonsmall cell lung cancer receiving atezolizumab: An ancillary analysis of the POPLAR and OAK studies

This study aimed to compare the differences in characteristics and prognoses between Asian and white patients receiving immunotherapy for nonsmall cell lung cancer (NSCLC). We studied 390 patients who received atezolizumab as part of the POPLAR or OAK trial, and analyzed the differences in baseline characteristics, outcomes and genetic mutations in blood samples between Asian and white patients. Overall survival (OS) was longer in Asian compared to white patients (median OS: 18.7 vs . 11.1 months; p = 0.005). Race was identified as an independent prognostic factor for OS (Asian vs . white: hazard ratio 0.647, 95% confidence interval 0.447–0.936, p = 0.021), together with performance status, histology, baseline sum of the longest tumor diameters (BLSLD) and number of metastatic sites. The two groups also differed in terms of characteristics including smoking history, BLSLD, epidermal growth factor receptor ( EGFR ) mutation frequency, programmed death‐ligand 1 expression and blood‐based tumor‐mutation burden. Blood mutations of STK11 , EGFR , KEAP1 , POLE , GRM3 , ATM and STAG2 were associated with treatment response, and TP53 , KEAP1 , APC , RB1 , CREBBP , EPHA5 and STAG2 mutations were associated with OS. The blood‐based mutation profiles differentiated between Asian and white patients, especially in relation to EGFR (23.8 vs . 8.5%), TP53 (30.2 vs . 46.9%) and STK11 (1.6 vs . 12.3%) mutations (all p < 0.05). The different clinicopathological features and mutation profiles in Asian and white patients may explain the superior outcome following atezolizumab treatment in Asian patients with NSCLC. The results of this study have important implications for further studies on racial disparities in relation to immunotherapy.